一种含VEGFR2突变的慢病毒载体及其在制备防治新生血管疾病药物中的应用和产品
By using a combination of lentiviral vectors containing VEGFR2 mutations to infect human retinal microvascular endothelial cells and inhibit VEGF signaling, the resistance problem of existing treatments for neovascular diseases has been solved, achieving effective prevention and treatment of neovascular diseases.
CN118956969BActive Publication Date: 2026-07-17THE THIRD AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- THE THIRD AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIV
- Filing Date
- 2024-07-09
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Current treatments for neovascularization are resistant to some patients, especially anti-VEGF drugs and VEGFR2 kinase inhibitors, which have limited effectiveness.
Method used
Using lentiviral vectors containing VEGFR2 mutations, human retinal microvascular endothelial cells were infected by combining LTR-EF1α-SpCas9n-sRT-U6-epegRNA-LTR and LTR-EF1α-MLH1dn-U6-ngRNA-LTR, thereby inhibiting VEGF-induced signal transduction events and preventing angiogenesis.
Benefits of technology
Effectively inhibiting VEGF-induced angiogenesis provides a new approach to the treatment of neovascular diseases, particularly the prevention and treatment of ocular neovascularization such as proliferative diabetic retinopathy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN118956969B_ABST
Abstract
本发明公开了一种含VEGFR2突变的慢病毒载体及其在制备防治新生血管疾病药物中的应用和产品，涉及生物技术领域。本发明提供了一种慢病毒载体组合，所述的慢病毒载体组合包括LTR‑EF1α‑SpCas9n‑sRT‑U6‑epegRNA‑LTR和 / 或LTR‑EF1α‑MLH1dn‑U6‑ngRNA‑LTR；所述的序列分别如SEQ ID NO:1和SEQ ID NO:2所示。通过将上述慢病毒组合传递到原代人视网膜血管内皮细胞中，能够抑制肿瘤血管生成和VEGFR2的自体磷酸化，为对抗与血管生成相关的疾病提供了一种有前景的方法。
Need to check novelty before this filing date? Find Prior Art